Trial reportCancer immunology, immunotherapy : CII2007
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells.
Trial report in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01278940 (Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2010Trial
- mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- mRNA vaccines in disease prevention and treatment.Signal transduction and targeted therapy · 2023Review
- Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects.Vaccines · 2023Article
- Article
- mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients.Vaccines · 2021Review
- Development and Delivery Systems of mRNA Vaccines.Frontiers in bioengineering and biotechnology · 2021Review
- Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.Haematologica · 2020Article
- Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready 'N Able to Improve Clinical Outcome?Cancers · 2020Review
- Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update.Pharmaceutics · 2020Review
- Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.Oncotarget · 2018Article
- Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.Cancer immunology, immunotherapy : CII · 2015Article
- Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma.Gene therapy · 2015Article
- Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity.Human vaccines & immunotherapeutics · 2015Article
- Tumor cell lysates as immunogenic sources for cancer vaccine design.Human vaccines & immunotherapeutics · 2014Review
- mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.Human vaccines & immunotherapeutics · 2013Review
- Antigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2012Article
- Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.Cancer immunology, immunotherapy : CII · 2012Article
- Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses.Cancer immunology, immunotherapy : CII · 2012Article
- Potential targets for pancreatic cancer immunotherapeutics.Immunotherapy · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have developed an individualized melanoma vaccine based on autologous dendritic cells (DCs) transfected with autologous tumor-mRNA. The vaccine targets the unique spectrum of tumor antigens in each patient and may recruit multiple T cell clones. In a recent phase I/II trial, we demonstrated T cell responses against vaccine antigens in 9/19 patients evaluable by T cell assays. Here, we report a follow-up study that was conducted to characterize interesting T cell responses and to investigate the effects of long-term booster vaccination. Two patients were selected for continued vaccine therapy. The clinical follow-up suggested a favorable clinical development in both patients. The immunological data (T cell proliferation/IFNgamma ELISPOT/Bioplex cytokine assays) indicated sustained T cell responses and suggested an enhancing effect of booster vaccinations. Both CD4(+) and CD8(+) T cell responses were demonstrated. From post-vaccination samples, we generated 39 T cell clones that responded specifically to stimulation by mRNA-transfected DCs and 12 clones that responded to mock-transfected DCs. These data clearly indicate a two-component vaccine response, against transfected and non-transfected antigens. T cell receptor (TCR) clonotype mapping, performed on 11 tDC-specific clones, demonstrated that 10/11 clones had different TCRs. The results thus indicate a broad spectrum T cell response against antigens encoded by the transfected tumor-mRNA. We generally observed mixed Th1/Th2 cytokine profiles, even in T cell clones that were confirmed to be derived from a single cell. This finding suggests that cytokine patterns after cancer vaccination may be more complex than indicated by the classic Th1/Th2 dichotomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.